Drugs / FF-10832
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05318573 | Jun 2022 → May 2029 expected | non-small cell lung carcinoma, urothelial carcinoma | Fujifilm Pharmaceuticals U.S.A., Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FF-10832 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05318573 ↗ |